In vitro study of sequential fluconazole and caspofungin treatment against candida albicans biofilms

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 1183-1186

  Sarkar, Semanti ^a   Uppuluri, Priya ^a   Pierce, Christopher G ^a   Lopez Ribot, Jose L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CALCINEURIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; HEAT SHOCK PROTEIN 90; MICAFUNGIN; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CELLULAR STRESS RESPONSE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ADAPTATION, PHYSIOLOGICAL; ANTIFUNGAL AGENTS; BIOFILMS; CALCINEURIN; CANDIDA ALBICANS; ECHINOCANDINS; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; HSP90 HEAT-SHOCK PROTEINS; MICROBIAL SENSITIVITY TESTS; STRESS, PHYSIOLOGICAL; TIME FACTORS;

EID: 84893508246     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01745-13     Document Type: Article

References (25)

1. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JR, Tolson J, Henderson T, Martone WJ. 1991. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am. J. Med. 91:86S-89S.
2. Beck-Sague C, Jarvis WR. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. Infect. Dis. 167:1247-1251.
3. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. 1999. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 29:239-244. http://dx.doi.org/10.1086/520192.
4. Kojic EM, Darouiche RO. 2004. Candida infections of medical devices. Clin. Microbiol. Rev. 17:255-267. http://dx.doi.org/10.1128/CMR.17.2.255-267. 2004.
5. Ramage G, Martinez JP, Lopez-Ribot JL. 2006. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 6:979-986. http://dx.doi.org/10.1111/j.1567-1364.2006.00117.x.
6. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780. http://dx.doi.org/10.1128/AAC.46.6.1773-1780.2002.
7. Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, Lopez-Ribot JL. 2002. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46:3591-3596. http://dx.doi.org/10.1128/AAC.46.11.3591-3596.2002.
8. Kucharíková S, Sharma N, Spriet I, Maertens J, Van Dijck P, Lagrou K. 2013. Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model. Antimicrob. Agents Chemother. 57:2365-2368. http://dx.doi.org/10.1128/AAC.02288- 12.
9. Ramage G, VandeWalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL. 2002. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob. Agents Chemother. 46:3634-3636. http://dx.doi.org/10.1128/AAC.46.11.3634-3636.2002.
10. Bachmann SP, Ramage G, VandeWalle K, Patterson TF, Wickes BL, Lopez-Ribot JL. 2003. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob. Agents Chemother. 47:3657-3659. http://dx.doi.org/10.1128/AAC.47.11. 3657-3659.2003.
11. Pierce CG, Uppuluri P, Tristan AR, Wormley FL, Jr, Mowat E, Ramage G, Lopez-Ribot JL. 2008. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc. 3:1494-1500. http://dx.doi.org/10.1038/ nport.2008.141.
12. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479. http://dx.doi.org/10.1128/ AAC.45.9.2475-2479.2001.
13. Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martinez M, Calabrese D, Sanglard D, Patterson TF. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45:2676-2684. http://dx.doi.org/10.1128/AAC.45.10.2676-2684.2001.
14. Shapiro RS, Robbins N, Cowen LE. 2011. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol. Mol. Biol. Rev. 75:213-267. http://dx.doi.org/10.1128/MMBR.00045-10.
15. Uppuluri P, Lopez-Ribot JL. 2010. An easy and economical in vitro method for the formation of Candida albicans biofilms under continuous conditions of flow. Virulence 1:483-487. http://dx.doi.org/10.4161/viru.1.6.13186.
16. Uppuluri P, Chaturvedi AK, Srinivasan A, Banerjee M, Ramasubramaniam AK, Köhler JR, Kadosh D, Lopez Ribot JL. 2010. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog. 6:e1000828. http://dx.doi.org/10.1371/journal.ppat.1000828.
17. Cowen LE, Steinbach WJ. 2008. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot. Cell 7:747-764. http://dx.doi.org/10.1128/EC.00041-08.
18. Cowen LE, Lindquist S. 2005. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309:2185-2189. http://dx.doi.org/10.1126/science.1118370.
19. Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, Cowen LE. 2009. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog. 5:e1000532. http://dx.doi.org/10.1371/journal. ppat.1000532.
20. Robbins N, Uppuluri P, Nett J, Rajendran R, Ramage G, Lopez-Ribot JL, Andes D, Cowen LE. 2011. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog. 7:e1002257. http://dx.doi.org/10.1371/journal.ppat. 1002257.
21. Cowen LE, Singh SD, Kohler JR, Collins C, Zaas AK, Schell WA, Aziz H, Mylonakis E, Perfect JR, Whitesell L, Lindquist S. 2009. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Natl. Acad. Sci. U. S. A. 106:2818-2823. http://dx.doi.org/10.1073/pnas.0813394106.
22. Uppuluri P, Nett J, Heitman J, Andes D. 2008. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob. Agents Chemother. 52:1127-1132. http://dx.doi.org/10.1128/AAC.01397- 07.
23. Kumamoto CA. 2005. A contact-activated kinase signals Candida albicans invasive growth and biofilm development. Proc. Natl. Acad. Sci. U. S. A. 102:5576-5581. http://dx.doi.org/10.1073/pnas.0407097102.
24. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. 2010. An insight into the antifungal pipeline: selected new molecules and beyond. Nat. Rev. Drug Discov. 9:719-727. http://dx.doi.org/10.1038/nrd3074.
25. LaFayette SL, Collins C, Zaas AK, Schell WA, Betancourt-Quiroz M, Gunatilaka AA, Perfect JR, Cowen LE. 2010. PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog. 6:e1001069. http://dx.doi.org/10. 1371/journal.ppat.1001069.